RT Journal Article
SR Electronic
T1 The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20162917
DO 10.1101/2020.07.29.20162917
A1 Klassen, Stephen A.
A1 Senefeld, Jonathon W.
A1 Johnson, Patrick W.
A1 Carter, Rickey E.
A1 Wiggins, Chad C.
A1 Shoham, Shmuel
A1 Grossman, Brenda J.
A1 Henderson, Jeffrey P.
A1 Musser, James
A1 Salazar, Eric
A1 Hartman, William R.
A1 Bouvier, Nicole M.
A1 Liu, Sean T. H.
A1 Pirofski, Liise-anne
A1 Baker, Sarah E.
A1 Helmond, Noud van
A1 Wright, R. Scott
A1 Fairweather, DeLisa
A1 Bruno, Katelyn A.
A1 Wang, Zhen
A1 Paneth, Nigel S.
A1 Casadevall, Arturo
A1 Joyner, Michael J.
YR 2021
UL http://medrxiv.org/content/early/2021/02/02/2020.07.29.20162917.abstract
AB To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case-series. Studies published between January 1, 2020 – January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random-effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher-titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures accessed public information and did not require ethical review as determined by the Mayo Clinic Institutional Review Board in accordance with the Code of Federal Regulations, 45 CFR 46.102, and the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll procedures accessed public information as sourced in the main text.